biologics

Is there a simple fix for the Part D discount program?A poll from the Biosimilars Council, a division of the Association for Accessible Medicines, has interesting findings about placing biosimilars and branded biologics on a level playing field to save money.
The December issue of Dermatology Times
The December issue of Dermatology TimesThe December issue of Dermatology Times highlights expected biologic developments to watch for in 2018, aesthetic technique pearls, and the basics of managing your dermatology practice, including budgeting, social media ethics and the legalities surrounding telemedicine.
Two asthma treatment recommendations for health organizationsAllergist Bradley Chipps, MD, shares research on how to fine-tune asthma management strategies.
Biosimilars can save billions of healthcare dollarsAnalysis from RAND helps frame the potential of biosimilars to reduce spending on biologics.
In atopic dermatitis, are you employing the therapeutic ladder approach?Treatment for atopic dermatitis isn’t always straightforward. In this article, a physician outlines treatment approaches.
Atopic dermatitis: Biologics to watch in 2018In this article, we take a look at the development of new treatments for atopic dermatitis.
Two Companies Announce Drug RecallsTwo companies have issued recalls on their products.
European Commission approves adalimumab for paediatric uveitisThe European Commission has approved adalimumab (Humira, AbbVie) as the first biologic treatment for chronic non-infectious anterior uveitis in paediatric patients from 2 years of age who have had an inadequate response to conventional therapy.
Avelumab safety profile is “acceptable”Immunotherapy improves Merkel cell carcinoma, but questions remain.
Guselkumab front and center at EADV Congress
Guselkumab front and center at EADV CongressIL-23 inhibitors represent one more very effective strategy for controlling psoriasis with PASI rates comparable to other biologics.